Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Total Debt: 2010-2024

Historic Total Debt for Cytokinetics (CYTK) over the last 12 years, with Dec 2024 value amounting to $104.7 million.

  • Cytokinetics' Total Debt rose 66.82% to $176.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.0 million, marking a year-over-year increase of 66.82%. This contributed to the annual value of $104.7 million for FY2024, which is 53.00% up from last year.
  • Cytokinetics' Total Debt amounted to $104.7 million in FY2024, which was up 53.00% from $68.5 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Total Debt ranged from a high of $104.7 million in FY2024 and a low of $46.2 million during FY2020.
  • For the 3-year period, Cytokinetics' Total Debt averaged around $79.3 million, with its median value being $68.5 million (2023).
  • Data for Cytokinetics' Total Debt shows a peak YoY skyrocketed of 53.00% (in 2024) over the last 5 years.
  • Cytokinetics' Total Debt (Yearly) stood at $46.2 million in 2020, then rose by 2.51% to $47.4 million in 2021, then soared by 36.74% to $64.8 million in 2022, then increased by 5.71% to $68.5 million in 2023, then spiked by 53.00% to $104.7 million in 2024.